Quarterly report pursuant to Section 13 or 15(d)

Acquisition of EHT (Details)

v3.22.2.2
Acquisition of EHT (Details) - USD ($)
Jun. 30, 2022
May 11, 2022
Dec. 31, 2021
Business Acquisition [Line Items]      
Number of shares to be issued per acquiree share (in shares)   1.95  
Deferred asset acquisition costs $ 842,193   $ 0
Emerald Health Therapeutics, Inc.      
Business Acquisition [Line Items]      
Number of shares to be issued per acquiree share (in shares)   1.95  
Equity interest issued or issuable (in shares) 416,270,585    
Dissent rights exercised, percent threshold   5.00%